Dear Editors,

We read with great interest the case reports by da Silva *et al.*[@bib0020], Carneiro *et al.*[@bib0025] and Eusébio *et al.*[@bib0030] published in the late issue of *GE Portuguese Journal of Gastroenterology*.

We would like to emphasize the clinical relevance of this topic regarding its, until recently, unrecognized features and share our small case-series experience ([Table 1](#tbl0005){ref-type="table"}).Table 1Clinical features of two cases of sprue-like enteropathy associated with olmesartan. F, Female; hypoK, hipokalemia; hypoAlb, hypoalbuminemia; hypoMg, hypomagnesemia.Table 1SexAgeTime of diagnosisClinical presentationDuration of symptomsLaboratorial findingsResponse to eviction of olmesartanTime of follow-up endoscopy/histologyResolution of histological changesF722014Chronic diarrhea; abdominal discomfort6 monthsNormocytic anemia; hypoK; hypoAlbClinical remission3 monthsYesF522015Chronic diarrhea4 monthsElectrolyte abnormalities (severe hypoK and hypoMg)Clinical remission6 monthsYes

Curiously, in both cases symptoms developed long (fourteen and ten months, respectively) after starting therapy. This has rarely been addressed and may difficult the diagnosis.

The primary care physicians were informed and advised to switch class of medication in these cases. There were no recurrences of symptoms during follow-up.
